ISSN 2149-2263 | E-ISSN 2149-2271
pdf
Volume : 25 Issue : 9 Year : 2021
Quick Search



Case-control study on PCSK9 R496W (rs374603772) and D374Y (rs137852912) mutations in Turkish patients with primary dyslipidemia [Anatol J Cardiol]
Anatol J Cardiol. 2018; 19(5): 334-340 | DOI: 10.14744/AnatolJCardiol.2018.86648

Case-control study on PCSK9 R496W (rs374603772) and D374Y (rs137852912) mutations in Turkish patients with primary dyslipidemia

Zuhal Eroğlu1, Aslı Tetik Vardarlı1, Zekeriya Düzgün1, Cumhur Gündüz1, Vildan Bozok Çetintaş1, Meral Kayıkçıoğlu2
1Department of Medical Biology,Faculty of Medicine, Ege University; İzmir-Turkey
2Department of Cardiology, Faculty of Medicine, Ege University; İzmir-Turkey

Objective: The aim of this study was to investigate the relationships between F216L (rs28942112), R496W (rs374603772), S127R (rs28942111), and D374Y (rs137852912) PCSK9 gain-of-function (GOF) mutations and primary dyslipidemia and serum lipid levels in patients with primary dyslipidemia.
Methods: In this case-control study, DNA was isolated from blood samples collected from patients diagnosed with primary dyslipidemia in cardiology outpatient clinic of Ege University (n=200) and healthy individuals (n=201). F216L, R496W, S127R, and D374Y GOF mutations in the PCSK9 gene were evaluated and genotyped according to the results of melting curve analysis performed in a real-time polymerase chain reaction (PCR) 480 instrument using specific primers for each mutation.
Results: There were statistically significant differences between the patient and individuals in control groups in the R496W and D374Y mutations (χ2=10.742 p=0.005; χ2=6.078 p=0.048, respectively). In addition, triglyceride levels in patients with primary dyslipidemia heterozygous for R496W and D374Y mutations were 12.8-fold (p=0.015) and 3.4-fold (p=0.03) higher than that in mutant and wild-type genotype, respectively. Additionally, in the entire study group (n=401), PCSK9 R496W and D374Y mutation carriers had increased total cholesterol (p=0.021), triglycerides (p=0.0001), HDL cholesterol (p=0.028), and low-density lipoproteins (LDL) cholesterol (p=0.028) levels. However, F216L (rs28942112) and S127R (rs28942111) mutations were not detected in patients with primary dyslipidemia and healthy controls.
Conclusion: We conclude that the PCSK9 R496W (rs374603772) and D374Y (rs137852912) GOF mutations may be significant risk factors in the development of primary dyslipidemia and may have significant impact on lipid parameters in general population.

Keywords: primary dyslipidemia, PCSK9, R496W, D374Y

Zuhal Eroğlu, Aslı Tetik Vardarlı, Zekeriya Düzgün, Cumhur Gündüz, Vildan Bozok Çetintaş, Meral Kayıkçıoğlu. Case-control study on PCSK9 R496W (rs374603772) and D374Y (rs137852912) mutations in Turkish patients with primary dyslipidemia. Anatol J Cardiol. 2018; 19(5): 334-340

Corresponding Author: Zuhal Eroğlu, Türkiye